Trials / Terminated
TerminatedNCT01058759
Taxotere-Enoxaparin-(ENOXA)-Study
Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | |
| OTHER | No Enoxaparin |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-01-29
- Last updated
- 2018-08-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01058759. Inclusion in this directory is not an endorsement.